Condition: Menstrual Migraine · Sponsor: Pfizer
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic Specialty Building | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic Arizona | Scottsdale, Arizona, United States | Recruiting |
| Hope Clinical Research, Inc. | Canoga Park, California, United States | Recruiting |
| Axiom Research | Colton, California, United States | Recruiting |
| Diablo Clinical Research, Inc. | Walnut Creek, California, United States | Recruiting |
| VIN - Aventura | Aventura, Florida, United States | Recruiting |
| Velocity Clinical Research, Hallandale Beach | Hallandale, Florida, United States | Recruiting |
| Jacksonville Center for Clinical Research | Jacksonville, Florida, United States | Recruiting |
| Urban Family Practice Associates | Marietta, Georgia, United States | Recruiting |
| Clinical Research Atlanta | Stockbridge, Georgia, United States | Recruiting |
| St Luke's Clinic - Neurology | Meridian, Idaho, United States | Recruiting |
+ 111 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06641466